Association between aspirin dose and outcomes in patients with acute Kawasaki disease

Association between aspirin dose and outcomes in patients with acute Kawasaki disease - Association between aspirin dose and outcomes in patients with acute Kawasaki disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049641

Enrollment

10000

Registered

2022-11-29

Start date

2022-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient treated by IVIG

Exclusion criteria

Exclusion criteria: Patient doesn't treated by IVIG

Design outcomes

Primary

Measure	Time frame
The primary outcome was the occurrence of CAAs upon discharge. CAAs were identified with a recorded diagnosis of CAAs (ICD-10 code: I25.4) and/or text data of CAAs in the Japanese language.	—

Secondary

Measure	Time frame
The secondary outcomes were IVIG resistance, length of stay, medical costs, and adverse events.	—

Countries

Japan

Contacts

Public ContactTakanori Suzuki

Fujita Health Universty Department of pediatrics

takanori-s@axel.ocn.ne.jp+819025786815

Outcome results